Advertisement

Topics

FDA Approves Yupelri for Maintenance Treatment of Adult Patients with COPD

16:34 EST 9 Nov 2018 | Speciality Pharma Journal

DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Mylan N.V. (NASDAQ: MYL) (“Mylan”) today announced that the U.S. Food and Drug Administration (FDA) has approved the  New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease …

Original Article: FDA Approves Yupelri for Maintenance Treatment of Adult Patients with COPD

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Yupelri for Maintenance Treatment of Adult Patients with COPD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...